Estimate criteria for efficacy of treatment in benign prostatic hyperplasia

International Journal of Urology

Volumn 3, Issue 4, 1996, Pages 267-273

  Homma, Yukio ^a   Kawabe, Kazuki ^a   Tsukamoto, Taiji ^b   Yamaguchi, Osamu ^c   Okada, Kiyoki ^d   Aso, Yoshio ^e   Watanabe, Hiroki ^f   Okajima, Eigoro ^g   Kumazawa, Joichi ^h   Yamaguchi, Takuhiro ^a   Ohashi, Yasuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d NIHON UNIVERSITY   (Japan)

^e FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g NARA MEDICAL UNIVERSITY   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

Author keywords

Benign prostatic hyperplasia; Criteria; Treatment efficacy

Indexed keywords

ANATOMY; ARTICLE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SYMPTOM; TREATMENT OUTCOME;

EID: 9444294059     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00532.x     Document Type: Article

References (20)

1. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-89.
2. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC, The Writing Committee. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of thirteen participating institutions evaluating 3885 patients. J Urol 1990;141:243-247.
3. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group. J Urol 1990;144:908-911.
4. Servadio C, Braf Z, Siegel Y, Leib Z, Saranga R, Lindner A. Local thermotherapy of the benign prostate: a 1-year follow-up. Eur Urol 1990;18:169-173.
5. Homma Y, Aso Y. Transurethral microwave thermotherapy for benign prostatic hyperplasia: a 2-year follow-up study. J Endourol 1993;7:261-265.
6. Kirby RS, Heard SR, Miller P, Eardley I, Holmes S, Vale J, Bryan J, Lus S. Use of the ASI titanium stent in the management of bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 1992;148:1195-1197.
7. Donatucci CF, Berger N, Kreder KJ, Donohue RE, Raife MJ, Crawford ED. Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. Urology 1993;42:42-49.
8. Takahashi S, Homma Y, Minowada S, Aso Y. Transurethral ultrasound-guided laser induced prostatectomy (TULIP) for benign prostatic hyperplasia: clinical utility at 1 year follow-up and imaging analysis. Urology 1994;43:802-807.
9. Kabalin JK. Laser prostatectomy performed with a right angle firing neodymium: Yag laser fiber at 40 watts power setting. J Urol 1993;150:95-99.
10. Madersbacher S, Kratzik C, Szabo N, Susani M, Vingers L, Marberger M. Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol 1993;23(suppl 1):39-43.
11. Holtgrewe HL. Guidance for clinical investigations of devices used for the treatment of benign prostatic hyperplasia. J Urol 1993;150:1588-1590.
12. Barry MJ, Fowler FJ Jr, O'Leary MA, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148:1549-1557.
13. Barry MJ, Cockette ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150:351-358.
14. Mebust WK, Bosch R, Donovan J, Okada K, O'Leary MA, Villers A. Symptom evaluation, quality of life and sexuality. In: Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds) The 2nd international consultation of benign prostatic hyperplasia. Paris: Pitie Salapatiere, 1993:131-138.
15. Aso Y, Boccon-Gibob L, Brendler CB, Calais Da Silva F, Cockett ATK, Fowler JE, Homma Y, Moriyama N, Okajima E, Richard F. Clinical Research Criteria. In: Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds) The 2nd international consultation of benign prostatic hyperplasia. Paris: Pitie Salapatiere, 1993:343-360.
16. Homma Y, Imajo C, Kawabe K, Aso Y. Response criteria for the therapeutic efficacy of treatment for benign prostatic hyperplasia. Int J Urol 1995;2:33-38.
17. Bruskewitz RC, Iversen P, Madsen PO. Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982;20:602-604.
18. Abram PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979;51:129-134.
19. Poulsen AL, Schou J, Puggaard L, Torp-Pedersen S, Nordling J. Prostatic enlargement, symptomatology and pressure/flow evaluation: interrelations in patients with symptomatic BPH. Scand J Urol Nephrol 1994; 157(suppl):67-73.
20. Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S. Bladder outlet obstruction versus impaired detrusor contractility: the role of outflow. J Urol 1991;145:810-812.